Minute Insight: Big Medtechs Usually Do Well During High Inflation, But Not in 2021

A new analysis from Wells Fargo found that the big medtech stocks typically perform at least as well as the overall market when inflationary expectations are high, but 2021 defied that trend.

Minute Insight

Medtech companies are mostly a safe investment during periods of high inflation, but 2021 is an exception to that pattern, a new analysis from Wells Fargo found.

The US is currently in a period of relatively high inflation. The US Bureau of Labor Statistics’ “all items” price index rose 6.2% for the 12 months ending in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Minute Insights

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.